31 May 2024 - The Biosafety Advisory Council issues a positive advice (with conditions) for this deliberate release
File:
Trial reference:
Phase 3, open-label, single-arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-R338L) in adult male participants with moderately severe to severe hemophilia B (FIX:C ≤2%) (BeneGene-2)